Drugs / P10s-PADRE
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02938442 | Jan 2019 → Jan 2023 | triple-negative breast carcinoma | University of Arkansas | Completed | No outcome recorded |
| Phase 1/2 | NCT02264236 | Oct 2015 → Jun 2021 | lung neoplasm | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02229084 | Jan 2015 → Jan 2023 | breast cancer | University of Arkansas | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03003195 | Mar 2021 | metastatic malignant neoplasm | University of Arkansas | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P10s-PADRE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02264236 ↗ |
| Modality | Peptide | “P10s-PADRE, a peptide mimotope-based vaccine” NCT02229084 ↗ |
| Route | Subcutaneous | “immunized by SC administration of P10s-PADRE vaccine” NCT02229084 ↗ |